Meeting
2018 Gastrointestinal Cancers Symposium
Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy.
Authors
Toshihiro Kudo
Osaka University Graduate School of Medicine, Osaka, Japan
Toshihiro Kudo , Takeshi Kato , Yoshinori Kagawa , Daisuke Sakai , Taroh Satoh , Yuichiro Doki , Masaki Mori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000018968
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 821)
DOI
10.1200/JCO.2018.36.4_suppl.821
Abstract #
821
Poster Bd #
M20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.
First Author: Miao Wang
Poster
2023 ASCO Annual Meeting
A phase II study of regorafenib plus sintilimab as salvage-line treatments in non–MSI-H metastatic colorectal cancer (mCRC).
First Author: Rui Liu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study.
First Author: Carlo Signorelli
Poster
2022 ASCO Annual Meeting
REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort.
First Author: Sophie Cousin